ID: ALA4063548

Max Phase: Preclinical

Molecular Formula: C17H15BrN2S

Molecular Weight: 359.29

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Brc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3

Standard InChI:  InChI=1S/C17H15BrN2S/c18-13-3-4-16-15(8-13)14-5-7-20(11-17(14)21-16)10-12-2-1-6-19-9-12/h1-4,6,8-9H,5,7,10-11H2

Standard InChI Key:  NFJCZGHFENHITA-UHFFFAOYSA-N

Associated Targets(non-human)

Cytochrome P450 17A1 516 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 359.29Molecular Weight (Monoisotopic): 358.0139AlogP: 4.62#Rotatable Bonds: 2
Polar Surface Area: 16.13Molecular Species: NEUTRALHBA: 3HBD: 0
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.33CX LogP: 4.24CX LogD: 4.20
Aromatic Rings: 3Heavy Atoms: 21QED Weighted: 0.66Np Likeness Score: -1.76

References

1. Wang M, Fang Y, Gu S, Chen F, Zhu Z, Sun X, Zhu J..  (2017)  Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.,  132  [PMID:28350999] [10.1016/j.ejmech.2017.03.037]

Source